Spyre Therapeutics, Inc. · NASDAQ:SYRE
King-Jones Heidy sold 28,399 Spyre Therapeutics, Inc. shares (Form 4)
Traded Sep 1 to Sep 2, 2026 · Filed Sep 3, 2026
From Sep 1 to Sep 2, 2026, King-Jones Heidy (See Remarks) sold 28,399 Spyre Therapeutics, Inc. shares at an average US$87.35 for US$2.48M under a trading plan, leaving 2,845 shares. Filed Sep 3, 2026 (Form 4).
- Sold
- 28,399 shares
- Price
- US$87.35 average (US$86.40 to US$90.00)
- Value
- US$2.48M
- Holding after
- 2,845 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- See Remarks
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Common Stock | Option exercise | 27,999 | US$14.50 | 30,844 | Direct |
| Sep 1, 2026 | Common Stock | Sale | 4,845 | US$86.40 | 25,999 | Direct |
| Sep 1, 2026 | Common Stock | Sale | 16,548 | US$87.20 | 9,451 | Direct |
| Sep 1, 2026 | Common Stock | Sale | 6,206 | US$88.17 | 3,245 | Direct |
| Sep 1, 2026 | Common Stock | Sale | 400 | US$89.38 | 2,845 | Direct |
| Sep 2, 2026 | Common Stock | Option exercise | 400 | US$14.50 | 3,245 | Direct |
| Sep 2, 2026 | Common Stock | Sale | 400 | US$90.00 | 2,845 | Direct |
Source
Related
- Spyre Therapeutics, Inc.
- King-Jones Heidy
- Spyre Therapeutics, Inc. shareholders
- Form 4 · King-Jones Heidy · Oct 2, 2026
- Schedule 13D/A · Harwin Peter Evan · Oct 9, 2026
- Form 4 · Burrows Scott L · Oct 2, 2026
- Form 4 · Turtle Cameron · Oct 2, 2026
- Schedule 13G · Paradigm Biocapital Advisors LP · Oct 1, 2026
- Form 4 · Burrows Scott L · Sep 3, 2026